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EDITORIAL COMMENT
Improving the Evaluation of Left
Ventricular Systolic Function
With Intravenous Perfluorocarbon
Ultrasound Contrast: Will
Suboptimal Echocardiograms
Become an Endangered Species?*
Thomas R. Porter, MD, FACC
Omaha, Nebraska
Over the past five years, intravenous ultrasound contrast
imaging has gone from a technique that had a few limited
right-sided applications (e.g., detecting a patent foramen
ovale) to one that has the potential to become an all-
encompassing imaging technique for both the determina-
tion of global and regional left ventricular (LV) systolic
function and the rapid assessment of myocardial perfusion.
If this potential becomes a reality, functional perfusion
imaging will be possible in clinical situations where other
imaging techniques (radionuclide imaging, computed to-
mography, right and left heart catheterization) simply can-
not go—to the bedside. In this issue of the Journal, Reilly et
al. (1) take one step toward the achievement of this goal by
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demonstrating the value of harmonic imaging with intrave-
nous Optison during bedside transthoracic echocardiogra-
phy in the intensive care unit (ICU) (1). Seventy patients,
examined from April to June 1998, were randomly evaluated
to determine whether harmonic imaging with an intrave-
nous ultrasound contrast agent improved the reader’s con-
fidence in assessing wall motion and the global LV ejection
fraction. They found that contrast imaging permitted the
interpretation of 76% of the segments that could not be seen
with standard imaging. More importantly, the authors
found that they could interpret LV ejection fractions in 11
of the 16 patients in whom ejection fractions were uninter-
pretable with standard imaging and in 4 of the 9 patients
whose ejection fractions were uninterpretable with har-
monic imaging alone. Contrast echocardiography signifi-
cantly changed the estimation of ejection fractions deter-
mined with standard imaging in 31 of the 70 patients.
These data demonstrate the marked potential of intravenous
contrast agents in intensive care settings, even when com-
pared with standard harmonic imaging alone.
The importance of intravenous perfluorocarbon contain-
ing microbubbles. The findings of Reilly et al. (1) dem-
onstrate that intravenous perfluorocarbon containing micro-
bubbles can significantly improve the quality of the
echocardiogram in the ICU. Previous studies using room air
containing microbubbles (Levovist and Albunex [2,3]) have
failed to demonstrate that these contrast agents added
significantly to the endocardial border enhancement of
harmonic imaging alone. Unlike these studies, Reilly et al.
(1) demonstrate the value of both harmonic imaging and
perfluorocarbon containing microbubbles. Although har-
monic imaging improved the quality of wall motion as
compared with standard imaging, more than 20 patients in
the ICU had a significant change in their ejection fraction
estimation after the injection of intravenous Optison as
compared with harmonic imaging alone. Although Reilly et
al. (1) did not compare Optison with room air containing
microbubbles, the value of perfluorocarbon containing mi-
crobubbles over room air containing microbubbles in delin-
eating endocardial borders has been described in a recent
phase III multicenter trial using the perfluorocarbon emul-
sion EchoGen (4).
Study limitations. Although the report by Reilly et al. (1)
is very important, it did not address some clinically relevant
questions regarding the accuracy and utility of contrast
echocardiography. First, we do not know if the increased
“surety” after intravenous Optison correlated with increased
accuracy. Because no comparative procedures were done on
any of the patients (e.g., radionuclide imaging, left ventricu-
lography), we cannot be sure that the ejection fractions with
contrast imaging were entirely correct. For example, both
diagnostic ultrasound pressures and LV systolic pressures
destroy contrast microbubbles. Therefore, it is possible that
the end-systolic images with contrast echocardiography
falsely appeared smaller than they actually were owing to
destroyed contrast agent. Hundley et al. (5) have shown,
however, that there is a strong correlation between end-
diastolic and end-systolic volumes obtained after contrast
opacification with intravenous EchoGen and those obtained
with magnetic resonance imaging. In this study, use of an
intravenous contrast agent improved the number of ejection
fractions that were correctly classified by echocardiography
from 71% to 94%. Furthermore, the improved accuracy of
contrast echocardiography was seen for ejection fractions
that ranged from ,35% to .50% (2).
Secondly, the authors (1) do not relate to us in what
direction contrast imaging changed the ejection fraction—
for the better or for the worse. For example, are the 44% of
cases in which a significant change in ejection fractions
occurred after use of contrast agent mainly the result of
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underestimations of ejection fractions during standard im-
aging (because of poor definition of end-systolic borders) or
is there a large percentage of cases for which we are
overestimating ejection fractions with standard imaging and
missing important wall motion abnormalities (because of
poor apical endocardial definition)? The clinical implica-
tions of this report are contingent on not only knowing
whether we can improve endocardial borders with intrave-
nous contrast agents, but also identifying what kind of
change the addition of contrast agent makes in the diag-
nostic and therapeutic management of these patients. These
data still have not been presented by any investigators in the
field, to my knowledge.
Conclusions. The findings of Reilly et al. (1) indicate that
intravenous perfluorocarbon containing microbubbles may
have a significant impact on patient management in the
ICU. Instead of having nearly 25% of the studies in which
ejection fractions cannot be determined, harmonic ultra-
sound imaging with Optison may enable us to determine
ejection fractions in over 95% of cases. Furthermore, intra-
venous Optison may prevent the misinterpretation of ejec-
tion fractions in over 40% of studies. These findings indicate
that suboptimal transthoracic studies with echocardiography
may become a rare entity in the twenty-first century.
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